Ginsenoside Rh4-regulated macrophage polarization and oxidative stress in septic myocardial injury Authors: Bingxin Huang, Yue Tang, Xinpeng Jiang, Hongtao Shen, Yidi Yang, Ling Jing, Hang Yang, Yunpeng Ling, Mowei Song Published: 2026 ABSTRACT AbstractSeptic cardiomyopathy (SCM) is a severe complication of sepsis. The therapeutic potential of Ginsenoside Rh4 (Rh4) in SCM remains unclear. This study aimed to investigate the effects and mechanisms of Rh4 on SCM using both in vivo and in vitro approaches. In the in vivo experiments, Rh4 significantly reduced the mortality rate in SCM mice, improved ejection fraction and diastolic function, and protected myocardial cell mitochondria, thereby alleviating myocardial cell injury. Transcriptomic sequencing, ELISA, and PCR results suggested that Rh4 reduced inflammatory cytokines in myocardial tissues, likely through the inhibition of the NF-κB signaling pathway. This effect was associated with a reduction in pro-inflammatory M1 macrophages and an increase in the proportion of reparative M2 macrophages. Additionally, Rh4 alleviated myocardial cell apoptosis and attenuated myocardial fibrosis at later stages. In vitro, we found that Rh4 reduced LPS-induced macrophage polarization and promoted the polarization of macrophages into anti-inflammatory M2 macrophages. Moreover, flow cytometry analysis revealed that Rh4 decreased reactive oxygen species (ROS) production in HL-1 cardiomyocytes, with the mechanism linked to the activation of the Keap1/Nrf2/HO-1 signaling pathway. Finally, Rh4 treatment significantly inhibited the pro-apoptotic effects of LPS on HL-1 cells. In conclusion, Rh4 improves heart function by reducing macrophage polarization and ROS generation, protecting myocardial cell mitochondria, and reducing myocardial cell apoptosis.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-46054-3.Keywords: Sepsis, Myocardial injury, Ginsenoside Rh4, Oxidative stress, Apoptosis, MacrophageSubject terms: Cardiology, Cell biology, Diseases Introduction Sepsis is caused by a dysregulated response to infection and often leads to multiple organ dysfunction. Septic cardiomyopathy (SCM) is a complication of sepsis that increases the risk of death1,2. The main symptoms are persistent hypotension, arrhythmia, acidosis, and body temperature fluctuations. Circulatory failure appears rapidly if treatment is delayed3,4. A 2023 meta-analysis database (Cochrane Central Register of Controlled Trials, MEDLINE, and Embase) found a prevalence of septic cardiomyopathy of 20% in patients with sepsis5. Usually, SCM patients have a severe reduction in the left ventricular ejection fraction (LVEF) because of myocardial ischemia and acute cardiac dysfunction6. However, strategies to prevent or treat SCM are lacking. Therefore, new strategies to treat or prevent SCM are urgently needed. Several factors contribute to myocardial dysfunction in SCM patients, namely uncontrolled inflammation, oxidative stress, and cardiomyocyte apoptosis7,8. Sepsis patients often have metabolic disorders, changes in hormone levels, massive release of proinflammatory mediators, and oxidative stress damage caused by tissue ischemia and hypoxia. These phenomena lead to increases in reactive oxygen species (ROS) levels, apoptosis induction, and tissue/organ dysfunction9. The rapid increase in proinflammatory factors in circulating blood impairs mitochondrial functions, which results in excessive apoptosis of myocardial cells because of the lack of adenosine triphosphate. After myocardial injury, serum concentrations of creatine kinase (CK-MB) and cardiac troponin T (cTnT) increase rapidly. Nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) have important roles in the inflammatory response and apoptosis regulation, which may also participate in SCM pathogenesis10. NF-κB is an important molecule that regulates inflammation when the body responds to sepsis. Increased levels of glucocorticoids, tumor necrosis factor (TNF)-α, IL-1β, and ROS in blood and tissues induce apoptosis and lead to tissue/organ dysfunction11. Apoptosis is regulated by the extracellular microenvironment and three apoptosis pathways: death receptor, mitochondrial, and endoplasmic reticulum stress. Apoptosis is initiated in myocardial tissue of sepsis mice and overexpression the B-cell lymphoma (Bcl)-2 protects against myocardial dysfunction8. In recent years, ginsenoside Rh4 (Rh4), a bioactive saponin derived from Panax ginseng, has garnered attention for its potential therapeutic effects in various inflammatory diseases. Rh4 has been shown to possess anti-inflammatory12, antioxidant13, and cardioprotective properties14, which may offer promise for the treatment of sepsis and its complications, including myocardial injury. Several studies have reported that Rh4 exerts its effects through the modulation of key signaling pathways such as NF-κB, MAPK, and Nrf2, which are involved in inflammatory responses, oxidative stress, and cellular survival15. Additionally, Rh4 has demonstrated a capacity to protect myocardial cells from ischemic injury and to reduce the production of pro-inflammatory cytokines, which are central to the development of sepsis-induced myocardial damage14. The potential of Rh4 to treat SCM is attributed to its multifaceted pharmacological actions. By reducing inflammation, mitigating oxidative stress, and improving mitochondrial function, Rh4 may help restore cardiac function and attenuate the pathological changes associated with sepsis-induced cardiomyopathy. Given the growing interest in Rh4 as a therapeutic agent and the need for novel treatments for sepsis-associated heart damage, this study aims to explore the efficacy of Rh4 in mitigating SCM, providing a foundation for future clinical applications in sepsis management. In this study, we established a model of SCM by intraperitoneal injection of LPS and investigated the protective effect and mechanism of Rh4 during SCM development. Materials and methods Animals Sixty healthy, specific pathogen-free, male C57BL/6 mice (18–22 g) were obtained from the Animal Center of the Third Hospital Affiliated to Peking University. Mice had free access to food and water. Ginsenoside Rh4 (Rh4, MedChemExpress (MCE), USA, > 98% pure) was dissolved in DMSO. After acclimation for 1 week, mice were randomly divided into three groups (n = 15 per group): The experimental mice were randomly divided into three groups: the sham group (intraperitoneal injection of normal saline without LPS injection), the LPS group (intraperitoneal injection of LPS (10 mg/ml) for modeling and oral administration of PBS), and the LPS + Rh4 group (intraperitoneal injection of LPS and oral administration of Rh4 at 80 mg/kg). The dosage and administration method of Rh4 were based on previous studies16. For survival analysis, A total of 45 mice were used and randomly divided into three groups (n = 15 per group), and monitored continuously for 48 h after LPS injection. For echocardiography and subsequent analyses, surviving mice (n = 5 per group) were randomly selected for echocardiography to avoid selection bias. This study is reported in accordance with ARRIVE guidelines (https://ariveguidelines.org). All animal care and experimental procedures followed guidelines for laboratory animal care and use, All animal experiments were approved by the Ethical Committee of Laboratory Animal Science Research of Peking University Third Hospital (Approval No. LA20240180). All methods were performed in accordance with the relevant guidelines and regulations. Euthanasia was performed by exposing mice to isoflurane, inducing with 5–6% and maintaining at 3–4% in a sealed chamber until death. Cessation of vital signs (heartbeat and breathing) and fixed, dilated pupils confirmed death. Echocardiography Forty-eight hours after LPS injection, echocardiography was performed with a Vevo2100 high resolution small animal ultrasound imager. Images were collected by an experienced operator who did not know the experimental design. The left ventricular ending diastolic diameter (LVEDD) and left ventricular ending systolic diameter (LVESD) were measured by M-mode echocardiography at the level of the papillary muscle in the parasternal short axis section. The left ventricular short axis shortening rate (LVFS) and LVEF were calculated by VisualSonics software. Transmission electron microscopy (TEM) The ultrastructure of left ventricular tissue was observed under a transmission electron microscope (Tecnai 20 U-Twin; Philips, Amsterdam, the Netherlands). Samples of fresh left ventricular tissue were fixed in 2.5% glutaraldehyde overnight at 4 °C and then post-fixed with 1% osmium tetroxide for 1 h. After embedding in resin, ultrathin sections (70 nm thick) were stained with 2% uranium acetate for 30 min and lead citrate for 10 min. Thirty randomly selected transmission electron micrographs from at least three animals per group were analyzed using ImageJ. Transcriptomic analysis The sequencing data were transformed into sequencing sequences by CASAVA Base Calling analysis, followed by sequencing quality distribution check on Illumina platform and gene expression analysis. Differentially expressed genes (DEGs) were identified by |log2 (Fold Change) |≥ 1.0 in gene expression with a p‐value < 0.05. Real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR) Real-time PCR was performed using ChamQ SYBR qPCR Master Mix (TaKaRa, Japan) in accordance with the manufacturer’s instructions. mRNA expression of β-actin was used to normalize target gene expression. Relative quantification was performed by the 2 − ΔΔCT method. The primers were as follows: TNF-α (for-ward 5ʹ-CGTCGTAGCAAACCACCAAG-3ʹ, reverse 5ʹ-GAGATAGCAAATCGGCTGACG-3ʹ), ccl2 (forward 5′‐TAAAAACCTGGATCGGAACCAAA‐3′, reverse 5′‐GCATTAGCTTCAGATTTACGGGT‐3′), IL-1β (forward 5ʹ-CTCACAAGCAGAGCACAAGC-3ʹ, reverse 5ʹ-TCCAGCCCATACTTTAGGAAGA-3ʹ), MCP-1 (forward 5ʹ-AGGGACTGAGGCACTCCAGA-3ʹ, reverse 5ʹ-TGACGACGAGACTTCCAGACTACA-3ʹ), and GAPDH (forward 5ʹ-AAATGGTGAAGGTCGGTGTG-3ʹ, reverse 5ʹ-AGGTCAATGAAGGGGTCGTT-3ʹ). Enzyme-linked immunosorbent assays (ELISAs) Blood was collected from the orbital vein to separate serum. Levels of CK-MB (Elabscience, #E-EL-M0355), cTnT (Elabscience, #E-EL-M1801), IL-1β (Elabscience, #E-EL-M0037), Ccl2 (Nan Jing Jian Cheng Bioengineering Institute, H318-1), MCP-1(Elabscience, # E-EL-M3001) and TNF-α (Elabscience, #E-EL-M3063) were measured by ELISAs. Concentrations in the supernatant of cardiac tissues were also measured by ELISA kits, following the manufacturer’s instructions. Immunofluorescence staining After fixation in paraformaldehyde overnight at 4 °C, myocardial tissue was cut into serial coronal frozen sections of 10 μm in thickness The frozen sections were rinsed with PBS, permeabilized with 0.3% Triton, and blocked with serum. Sections were incubated overnight with a primary antibody at 4 °C refrigerator. The primary antibody was anti-active cleaved caspase-3 (1:100 dilution, 9664 T, Cell Signaling Technology), CD86 (1:100 dilution, ab119857, Abcam), CD206 (1:200 dilution, 24595 T, Cell Signaling Technology), NF-κB (1: 50 dilution, ab32536; Abcam). The secondary antibodies used were Alexa Fluor 488-conjugated goat anti-rat IgG (1:1000, Thermo Fisher, A48262) and Alexa Fluor 555-conjugated goat anti-rabbit IgG (1:1000, Thermo Fisher, A32732) for 1 h. The sections were counterstained with DAPI and then imaged under a fluorescence microscope (Olympus, Tokyo, Japan). Image-Pro plus 6.0 (Media Cyber-netics, San Diego, CA, USA) was used for analysis. Western blotting Western blotting was performed in accordance with a previous study. Myocardial tissue (100 mg) was lysed in RIPA lysis buffer to extract total protein. A Bicinchoninic Acid Assay kit (A045-4-2, Nan Jing Jian Cheng Bioengineering Institute) was used to measure the protein concentration. Protein samples (20 μg) were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis on 10% or 12% gels. Proteins were then transferred to nitrocellulose membranes. The membranes were blocked with 5% dry skim milk for 1 h at room temperature. Membranes were incubated at 4 °C overnight with primary antibodies against Kelch-like ECH-associated protein 1 (Keap1) (1:800, Cell Signaling Technology, Beverly, MA, USA), Nrf2(1:1000, Cell Signaling Technology, Beverly, MA, USA), HO-1(1:1000, Cell Signaling Technology, Beverly, MA, USA), Bax(1:1000, Cell Signaling Technology, Beverly, MA, USA), Bcl-2(1:1000, Cell Signaling Technology, Beverly, MA, USA) and β-actin(1:2000, Cell Signaling Technology, Beverly, MA, USA). The membranes were washed with TBST (EpiZyme Biotech) three times and then incubated with secondary antibodies for 1 h at room temperature. Membranes were developed and visualized using a gel imaging system (MG8600; Beijing Thmorgan Biological Technology, Beijing, China). Quantitative analysis was conducted using ImageJ (US National Institutes of Health, Bethesda, MD, USA) with normalization to β-actin expression. Data are expressed as the percentage of the control. Masson’s staining The hearts of SCM mice were fixed overnight in 4% paraformaldehyde. Ten-micrometer frozen sections were prepared and stained using the Masson staining kit according to the standard protocol (Solarbio, G1346, Beijing, china). The stained sections were then examined and photographed under an optical microscope (Model IX71, Olympus, Tokyo, Japan). Cell culture and treatment RAW264.7 macrophages were obtained from the Central Laboratory of Peking University Third Hospital. HL-1 cardiomyocytes were purchased from FuHeng Biology (Shanghai, China). RAW264.7 cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. HL-1 cells were cultured in MEM supplemented with 10% FBS at 37 °C in a humidified atmosphere containing 5% CO₂. For in vitro stimulation, cells were treated with lipopolysaccharide (LPS, 1 μg/mL) for 24 h. Rh4 was dissolved in DMSO and applied at a final concentration of 10 μM (unless otherwise specified). In Rh4 treatment groups, cells were pretreated with Rh4 for 1 h followed by LPS stimulation for the indicated duration. The final concentration of DMSO was ≤ 0.1% in all groups. Flow cytometry for ROS and apoptosis detection Intracellular ROS in HL-1 cells was detected using a ROS assay kit (CA1410, Solarbio, Beijing, China) according to the manufacturer’s instructions. Briefly, after treatment, cells were incubated with the fluorescent ROS probe (DCFH-DA provided in the kit) at 37 °C in the dark, washed with PBS, and analyzed by flow cytometry in the FITC channel. Mean fluorescence intensity (MFI) was used for quantification. Apoptosis was assessed using an Annexin V-FITC/PI apoptosis detection kit (KGA1107, KeyGen BioTECH, Jiangsu, China) following the manufacturer’s protocol. Cells were resuspended in 500 μL binding buffer, stained with Annexin V-FITC and PI, and then analyzed by flow cytometry. The apoptosis rate was calculated as the percentage of Annexin V–positive cells (early + late apoptosis). Data were analyzed using Kaluza software (Beckman Coulter). Statistical analyses SPSS 22.0 statistical software was used for data analysis and processing. Data are ex-pressed as means ± standard deviation. The normal distribution was detected via the Shapiro–Wilk test. For normally distributed data, ordinary one‐way ANOVA with Sidak’s post hoc test was performed. When the data were not normally distributed, Brown–Forsythe and Welch-ANOVA followed by Games–Howell post hoc test with Welch’s correction were performed. P < 0.05 was considered significant. Results Ginsenoside Rh4 (Rh4) alleviates Septic cardiomyopathy (SCM) and improves mouse survival Forty-eight hours after LPS injection, all mice in the control group had survived, five mice in the SCM group had survived and 10 mice in the SCM + Rh4 group had survived. Kaplan–Meier survival curves showed that the survival rate in SCM and SCM + Rh4 groups at 48 h after LPS injection was significantly lower than that in the sham group (P < 0.05 for both), whereas the survival rate in the SCM + Rh4 group was significantly higher than that in SCM groups (P < 0.05) (Fig. 1A). CK-MB and cTnT levels in SCM groups were increased significantly compared with those in the sham group (P < 0.05) (Fig. 1B,C). However, in the SCM + Rh4 group, serum levels of CK-MB and cTnT were decreased compared with SCM group. (P < 0.05). We assessed ultrastructural changes in myocardial mitochondria by Transmission electron microscopy (TEM). In the SCM group, extensive rupture of myocardial fibers, disordered arrangement of fiber bundles, swelling, vacuolar degeneration, and shrinkage of myocardial cells were seen. We also observed myocardial interstitial hyperemia, edema, an irregular shape and size of mitochondria, a small amount of local aggregation and distribution between muscle fibers, an incomplete membrane, cristae, a reduction of mitochondrial cristae, and fewer sarcoplasmic reticula. Additionally, breakage and lysis of fibers was evident in certain parts of the myocardium. Myocardial mitochondrial morphology was improved in the SCM + Rh4 group compared with that in the SCM group. Mitochondria became regular, and swelling and vacuolar degeneration were weakened (Fig. 1D). Transthoracic echocardiography was performed to evaluate cardiac function in sham, SCM, and SCM + Rh4 mice. Compared with sham controls, SCM mice exhibited a marked decline in left ventricular ejection fraction (LVEF) and fractional shortening (LVFS), indicating severe systolic dysfunction (Fig. 1F,G). Consistently, left ventricular end-systolic diameter (LVESD) was significantly increased in SCM mice, whereas left ventricular end-diastolic diameter (LVEDD) showed only modest changes (Fig. 1H,I), suggesting impaired contractile performance without evidence of significant left ventricular structural changes at this early stage. Rh4 treatment significantly improved LVEF and LVFS and reduced LVESD, while LVEDD remained largely unchanged, indicating that Rh4 primarily preserved systolic function without inducing major structural alterations of the left ventricle. In addition to myocardial protection, Rh4 also attenuated sepsis-induced hepatic and renal dysfunction, as evidenced by reduced serum ALT, AST, BUN, and creatinine levels (Supplementary Figure S3). Ginsenoside Rh4 (Rh4) alleviates Septic Myocardial Injury (SCM) and improves mouse survival. (A) Kaplan–Meier survival curves (n = 15 per group) (B) CK-MB level. (C) cTnT level. (D) Transmission electron micrographs of left ventricular specimens. Scale bar is 5 μm. (E) Representative echocardiographic images of mice. (F) Ejection fraction (EF). (G) Fractional shortening (FS). (H) Left Ventricular End-Systolic Diameter (LVESD). (I) Left Ventricular End-Diastolic Diameter (LVEDD). n = 5 per group. *P < 0.05 compared with the sham group. #P < 0.05 compared with the SCM group. CK-MB: creatine kinase-myocardial bound; SCM: Septic cardiomyopathy; cTnT: cardiac troponin T; Rh4: Ginsenoside Rh4. RH4 may protect cardiac function by alleviating cardiac inflammation The key genes were analyzed by RNAseq analysis of samples from the heart of SCM mice and SCM + Rh4 mice. A volcano map was used to express the different genes between the SCM mice heart and SCM + Rh4 mice heart. The gene P adj < 0.05 and |log2 (Fold Change) |≥ 1 were selected as differential expression genes (DEGs). A total of 594 DEGs (181 upregulated genes and 413 down-regulated genes) were identified (Fig. 2A). We performed GO enrichment analysis on the differentially expressed genes (DEGs). The results of the Biological Process (BP) analysis indicated that the DEGs were primarily associated with inflammation-related processes, such as neutrophil migration and monocyte aggregation (Fig. 2B). The Molecular Function (MF) clustering results revealed that the primary molecular functions of these DEGs included cell adhesion and immune response (Fig. 2C). Subsequently, we performed KEGG enrichment analysis on the differentially expressed genes and selected the 10 signaling pathways most closely related to inflammatory responses. We found that the TNF-α signaling pathway and the NF-κB signaling pathway might play critical roles among them (Fig. 2D). Finally, differential expression analysis of the downregulated genes after Rh4 treatment showed that the top 20 DEGs were predominantly related to inflammation, including genes such as CCL2, TNF, CD11b, and S100A8 (Fig. 2E). Rh4 significantly improved myocardial inflammation in SCM mice. (A) Volcano map. (B) Top 10 gene ontology (GO) enriched cellular component (CC) terms. (C) Top 10 gene ontology (GO) enriched molecular function (MF) terms. (D) KEGG enrichment analysis. KEGG pathways were identifiedand visualized using the KEGG database (Kanehisa Laboratories, www.kegg.ip/kegg/kegg1.html). (E) Heatmap. Rh4 alleviated myocardial inflammation in SCM mice, and its mechanism may be related to macrophage polarization mediated by the NF-κB signaling pathway Inflammatory cytokines or chemokines, such as TNF-α, CCl2, IL-1β, and MCP-1, were significantly increased in the myocardial tissue of SCM mice. However, in SCM rats treated with Rh4 (SCM + Rh4 group), the levels of these inflammatory factors were markedly reduced (Fig. 3A–D). The PCR results were consistent with the ELISA findings (Fig. 3E–H). Given that macrophages are the primary cell type influencing myocardial inflammation, we examined the differences between pro-inflammatory (CD86-positive) and anti-inflammatory (CD206-positive) macrophages in myocardial tissue. The results indicated that, compared with the sham group, SCM model mice exhibited an increased number of pro-inflammatory macrophages in myocardial tissue. However, in SCM mice treated with Rh4, the number of pro-inflammatory macrophages decreased, while the number of anti-inflammatory macrophages increased (Fig. 3I–K). In addition, we examined the levels of NF-κB protein in the myocardial tissue of the three groups of mice. The results showed that Rh4 significantly reduced the levels of NF-κB in myocardial tissue (Fig. 3L–M). Rh4 alleviated myocardial inflammation in SCM mice, and its mechanism may be related to macrophage polarization mediated by the NF-κB signaling pathway. (A–D) Representative the myocardial content of TNF-α, CCL2, IL-1β and MCP-1 through Elisa detection. (E–H) Representative qPCR assay results for mRNA expression levels of TNF-α, CCL2, IL-1β and MCP-1. (I) Representative immunofluorescence staining image displaying the expression of CD86 (green, M1 macrophage marker) and CD206 (red, M2 macrophage marker) stained with DAPI (blue). Scale bar is 50 µm. (J) Quantitative analysis of the number of CD86-positive cells (n = 3 per group). (K) Quantitative analysis of the number of CD206-positive cells (n = 3 per group). (L) Representative immunofluorescence staining image displaying the expression of CD86 (green, M1 macrophage marker), NF-κB (red) stained with DAPI (blue). Scale bar is 50 µm. (M) Quantitative analysis of mean fluorescence intensity NF-κB (n = 3 per group). Data are shown as means ± standard deviation. *Compared with the sham group, #compared with the SCM group. *or # means p < 0.05, **or ## means p < 0.01. ***or ### means p < 0.001. ns: not significant. Rh4 inhibited LPS-induced pro-inflammatory macrophage polarization in vitro We treated normal RAW 264.7 macrophages with LPS (1 μg/ml) for 24 h to induce the polarization of M0 macrophages into M1 macrophages. One of the markers of M1 macrophages is the positive expression of cytoplasmic iNOS protein, while the marker for M2 macrophages is the positive expression of CD206. We found that Rh4 effectively reduced the proportion of iNOS-positive macrophages induced by LPS and increased the proportion of CD206-positive macrophages (Fig. 4A–D). To further functionally validate macrophage polarization, we assessed the expression of representative pro-inflammatory cytokines. Consistent with the phenotypic changes, Rh4 significantly decreased the mRNA levels of IL-6, IL-1β, and TNF-α compared with the LPS group (Fig. 4E–G), indicating attenuation of pro-inflammatory macrophage activation. Rh4 inhibited LPS-induced pro-inflammatory macrophage polarization in vitro. (A) Representative immunofluorescence images of macrophage stained in green with iNOS (M1 macrophage marker), red with CD11b (all macrophage marker), and blue with DAPI. Scale bar = 50 μm. (B) Quantitative analysis of proportion of iNOS-positive cells. (C) Representative immunofluorescence images of macrophage stained in green with CD206 (M2 macrophage marker), red with CD11b (all macrophage marker), and blue with DAPI. Scale bar = 50 μm. (D) Quantitative analysis of proportion of CD206-positive cells. (E–G) mRNA expression levels of IL-6, IL-1β, and TNF-α assessed by qPCR. Data are shown as means ± standard deviation.*Compared with the sham group, #compared with the SCM group## means p < 0.01. ***or ### means p < 0.001. ns: not significant. Rh4 reduced apoptosis in myocardial tissue of SCM mice To further investigate the mechanism by which Rh4 alleviates myocardial inflammation and improves cardiac function, we examined the differences in apoptosis-related proteins in the myocardial tissue of SCM mice. Confocal microscopy results indicated significant apoptosis in the myocardial tissue of SCM mice, with a marked increase in activated caspase-3 protein (Fig. 5A,B), a key protein in the classical apoptosis pathway. However, in the myocardial tissue of the SCM + Rh4 group treated with Rh4, cleaved caspase-3 was significantly reduced. Additionally, WB results showed that another key protein in the classical apoptosis pathway, BAX, was markedly decreased in the SCM + Rh4 group, while the anti-apoptotic protein BCL2 was increased. Rh4 reduced apoptosis in myocardial tissue of SCM mice. (A) Representative immunofluorescence staining image displaying the expression of Cleaved caspase 3 (red, apoptosis marker) stained with DAPI (blue). Scale bar is 50 µm. (B) The number of positive cells per unit area. (n = 3). (C) The Bcl2 protein expression levels in each group were measured with Western blot. (D) The Bax protein expression levels in each group were measured with Western blot. (E) Statistical analysis of Bcl2 protein expression levels. (F) Statistical analysis of Bax protein expression levels. Data are shown as means ± standard deviation. The original blots are presented in Supplementary Material 1. *Compared with the sham group, #compared with the SCM group. *or # means p < 0.05, **or ## means p < 0.01. ***or ### means p < 0.001. Rh4 reduces ROS in cardiomyocytes by activating the Keap1/Nrf2/HO-1 signaling pathway, thereby mitigating LPS-induced cardiomyocyte apoptosis To investigate the mechanism by which Rh4 inhibits cardiomyocyte apoptosis, we treated HL-1 cardiomyocyte cell lines with LPS to induce apoptosis in vitro. In the LPS + Rh4 group, Rh4 was added to the regular culture medium. Confocal staining revealed a significant increase in reactive oxygen species (ROS) levels in cardiomyocytes treated with LPS, whereas RH4 treatment markedly reduced ROS accumulation (Fig. 6A,B). The results of flow cytometry were consistent with those observed in the confocal microscopy analysis. We found that LPS significantly increased intracellular ROS levels in cardiomyocytes, while Rh4 inhibited ROS production (Fig. 6C,D). This mechanism may be associated with the Keap1/Nrf2/HO-1 signaling pathway. Western Blot results indicated that Nrf2 expression was increased in cardiomyocytes treated with Rh4, along with enhanced expression of the antioxidant enzyme HO-1 (Fig. 6E–H). Rh4 significantly reduced LPS-induced cardiomyocyte apoptosis, as confirmed by Annexin V-FITC/PI flow cytometric analysis. (Fig. 6I,J). Rh4 reduces ROS in cardiomyocytes by activating the Keap1/Nrf2/HO-1 signaling pathway, thereby mitigating LPS-induced cardiomyocyte apoptosis. (A) Representative immunofluorescence images of HL-1 stained in red with ROS and blue with DAPI. Scale bar = 50 μm. (B) Quantitative analysis of immunofluorescence results for ROS mean fluorescence intensity in three groups (n = 3). (C) Flow cytometry results showed mean fluorescence intensity of ROS. (D) Quantitative analysis of flow cytometry results for ROS mean fluorescence intensity in three groups (n = 3). (E) The total cellular Keap1, Nrf2 and HO-1 protein expression levels in each group were measured with Western blot. (F–H) Statistical analysis of Keap1, Nrf2 and HO-1 protein expression levels. (I) Flow cytometry analysis of cell apoptosis in HL-1 cells. (J) Quantitative analysis of flow cytometry data for HL-1 apoptosis (n = 3). Data are shown as means ± standard deviation. The original blots are presented in Supplementary Material 1.*Compared with the sham group, #compared with the LPS group. *or # means p < 0.05, **or ## means p < 0.01. ***or ### means p < 0.001. Rh4 significantly reduced collagen secretion and improved myocardial fibrosis To further evaluate long-term structural changes, myocardial fibrosis was assessed at day 14 after LPS administration. The results showed that Rh4 treatment significantly reduced myocardial fibrosis in septic mice with myocardial injury. Specifically, the following observations were made: Firstly, immunohistochemical analysis revealed a marked increase in collagen type I and collagen type III in the myocardial tissue of SCM mice. However, both of these proteins were significantly reduced in the myocardial tissue of Rh4-treated mice (Fig. 7A,B). Secondly, Masson’s staining showed an increased area of blue fibrous tissue in the myocardial tissue of SCM mice (Fig. 7C). In contrast, the blue fibrous tissue area was greatly reduced in the tissue of Rh4-treated mice (Fig. 7D–F). Consistently, qRT-PCR analysis showed that Rh4 significantly decreased the mRNA expression levels of Col1a1, Col3a1, and α-SMA compared with the SCM group (Fig. 7G–I), indicating suppression of extracellular matrix deposition and myofibroblast activation. Rh4 significantly reduced collagen secretion in myocardial tissue, alleviated fibrosis, and improved cardiac structural changes. (A) Representative image of Collagen I immunohistochemistry. (B) Representative image of Col3a1 immunohistochemistry. Scale bar = 250 μm. (C) Heart masson staining. Fibrosis area (blue) and myocytes (red). Scale bar = 250 μm. Data are shown as means ± standard deviation. (D–F) Quantification of collagen I–positive area (D), collagen III–positive area (E), and fibrotic area assessed by Masson staining (F). (G–I) Relative mRNA expression levels of Col1a1 (G), Col3a1 (H), and α-SMA (I) in cardiac tissues, as determined by qRT-PCR.* Compared with the sham group, #compared with the SCM group. # means p < 0.05, ***or ### means p < 0.001. Discussion The present study demonstrates that ginsenoside Rh4 (Rh4) has potent therapeutic effects in alleviating sepsis-induced myocardial injury in a septic cardiomyopathy (SCM) mouse model. Our results show that Rh4 treatment significantly improved survival rates, cardiac function, and myocardial cell integrity, and it also reduced mitochondrial damage. These findings suggest that Rh4 exerts its beneficial effects through a combination of anti-inflammatory, antioxidative, and anti-apoptotic mechanisms. Importantly, the distinction between acute injury (within 48 h) and later-stage remodeling (day 14) in our study is consistent with the temporal progression reported in previous studies on sepsis-induced cardiomyopathy. Simultaneously, Rh4 activated the Keap1/Nrf2/HO-1 pathway to reduce oxidative stress, thereby alleviating apoptosis caused by the mitochondrial pathway. Furthermore, Rh4 protected against myocardial injury induced by LPS in vivo. Similar to other studies focusing on myocardial injury due to sepsis, we established a mouse model by intraperitoneal injection of LPS. We found that cardiac functions in mice with sepsis were significantly impaired, as manifested by increases in myocardial injury markers CK-MB and cTnT. However, CK-MB and cTnT were decreased and survival was increased after Rh4 treatment. Additionally, the levels of proinflammatory factors and ROS in the myocardium of mice with sepsis were increased significantly. Hence, sepsis caused irreversible damage to the myocardium through rapid production of several proinflammatory mediators and ROS. Myocardial injury in mice with sepsis is associated with inflammation. Excessive levels of proinflammatory cytokines aggravate existing damage to myocardial tissue. Pathogens entering a cell through specific receptors on the cell membrane encourage the cell to synthesize proinflammatory cytokines during sepsis. Pro-inflammatory M1 macrophages play a significant role in the progression of myocardial injury in SCM, contributing to extensive tissue damage. These macrophages secrete a variety of pro-inflammatory cytokines and reactive oxygen species (ROS), which exacerbate myocardial injury and inflammation. In contrast, M2 macrophages, which exhibit a repair phenotype, are involved in resolving inflammation and promoting tissue repair. M2 macrophages produce anti-inflammatory cytokines and growth factors that support tissue regeneration, reduce oxidative stress, and ultimately help mitigate the inflammatory damage caused by sepsis-induced myocardial injury17. The NF-κB signaling pathway plays a crucial role in regulating the polarization of macrophages toward the M1 or M2 phenotypes, and thus, it is a key mediator of the inflammatory response in various disease contexts18. We found that expression of NF-κB (p65) was increased significantly in the myocardial tissue of mice with sepsis. IL-1β, TNF-α, IL-6, and monocyte chemoattractant protein-1 levels were also increased significantly, which is consistent with a previous study on myocardial injury by sepsis. Activation of the NF-κB signaling pathway increases the secretion of IL-6 and TNF-α, which have major roles in sepsis-related organ damage. With the development of sepsis, LPS in the cell wall of Gram-negative bacteria recognize Toll-like receptor-4 and activates NF-κB19,20. The latter enters the nucleus from the cytoplasm, activates expression of target genes, and induces expression of downstream proinflammatory factors. Inflammatory factors such as TNF-α can lead to myocardial injury induced by sepsis by inhibiting Ca2 + transport, regulating the nitric oxide (NO) pathway, and degrading important contractile proteins21,22. Therefore, inhibiting activity of the NF-κB signaling pathway and reducing the release of proinflammatory factors may alleviate SCM. The most direct evidence that the oxidative stress response was enhanced was that the ROS level in the myocardial tissue of SCM mice was increased significantly. LPS promotes oxidative stress and increases production of ROS, the superoxide radicals and hydroxyl ions. LPS also increases the level of inducible nitric oxide synthase and produces a large amount of NO, which reacts with superoxide radicals, leading to the formation of peroxynitrite, which induces oxidation of lipids, proteins, and DNA. Furthermore, increases in ROS aggravate the inflammatory response, cause mitochondrial dysfunction, and damage myocardial cells. TEM clearly revealed the disappearance of mitochondrial cristae in the myocardial tissue of mice with sepsis. Nrf2 is regarded as an important antioxidant molecule because it activates various antioxidant enzymes that counteract oxidative stress. The Keap1/Nrf2 pathway is a critical signaling pathway in regulating myocardial oxidative stress injury. Upon dissociation from Keap1, Nrf2 translocases to the nucleus, where it activates the expression of downstream antioxidant enzymes, such as HO-123. In this experiment, it was also observed that Rh4 promotes the expression of both Nrf2 and HO-1. We reactivated this pathway using Rh4, resulting in a significant reduction in ROS levels. A recent study showed that Rh4 protects against myocardial injury. However, whether Rh4 reduces myocardial oxidative stress caused by sepsis was unknown. We found that Rh4 induced stabilization of Nrf2 protein through modification of cysteine in Keap1 and activated the Nrf2/HO-1 pathway. Eventually, increases in levels of ROS and proinflammatory factors promote cardio-myocyte apoptosis. Exploration of the mechanism revealed that the mitochondrion-mediated apoptosis pathway was significantly activated. The underlying mechanism of myocardial cell apoptosis is related to activation of caspase-3 and the apoptotic molecule Bax, and inhibition of the anti-apoptotic molecule Bcl-2. An increase in Bax expression and decrease Bcl-2 expression activates caspase-3, which leads to cardiomyocyte apoptosis. In our study, Bcl-2 expression was significantly increase by Rh4 treatment. However, expression of caspase-3 was down-regulated substantially by Rh4 treatment. Therefore, Rh4 exerted inhibitory effects on apoptosis of tubular myocardial cells in the pathogenesis of LPS-induced myocardial injury. Several limitations of the present study should be acknowledged. First, the protective effects of Rh4 were primarily evaluated using an LPS-induced sepsis-related cardiomyopathy model. Although this model is widely used and recapitulates key features of acute inflammatory cardiac dysfunction, it does not fully reflect the complexity of clinical sepsis or other forms of myocardial injury. Second, while this study focused on macrophage polarization, oxidative stress, and the Keap1/Nrf2/HO-1 signaling pathway, other potential mechanisms, including mitochondrial dysfunction, metabolic remodeling, and intercellular crosstalk within the cardiac microenvironment, were not explored and warrant further investigation. From a translational perspective, Rh4 is a naturally derived compound with demonstrated anti-inflammatory and antioxidative properties. However, its optimal dosage, long-term safety, and pharmacokinetic characteristics remain to be systematically evaluated before clinical application. Future studies employing clinically relevant models and large-animal experiments will be necessary to further assess the therapeutic potential of Rh4 in cardiac inflammatory injury. Finally, our study demonstrated that Rh4 reduced cardiac fibrosis in SCM mice, as shown by a decrease in collagen I and III expression and reduced fibrotic area in Masson’s trichrome staining. This reduction in fibrosis suggests that Rh4 not only protects myocardial cells from acute injury but also suggests a potential role in limiting long-term remodeling and scarring that contribute to heart failure in sepsis. Conclusion We explored the protective effects and mechanism of Rh4 in SCM mice. The findings from this study provide compelling evidence that Rh4 exerts its therapeutic effects through multiple mechanisms, including modulation of inflammation, macrophage polarization, apoptosis, oxidative stress, and fibrosis. By addressing these key pathological processes, Rh4 presents a promising therapeutic option for the treatment of sepsis-induced myocardial injury and offers a potential strategy for improving outcomes in septic patients with heart dysfunction. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 2. Author contributions Bingxin Huang: Writing- Original draft preparation, Writing- Reviewing and Editing, Methodology; Yue Tang: Methodology, Software, Validation; Xinpeng Jiang: Methodology, Data curation; Software, Validation; Hongtao Shen: Methodology, Software, Visualization; Yidi Yang: Visualization, Investigation; Ling Jing: Methodology, Visualization; Hang Yang: Methodology, Software, Conceptualization; Yunpeng Ling: Funding acquisition, Conceptualization, Methodology; Mowei Song: Funding acquisition, Supervision, Conceptualization. Funding This work was supported by The National Natural Science Foundation of China (Grant Numbers 82172538), Heilongjiang Province Traditional Chinese Medicine Research Management Project (ZHY2024-158, ZHY2024-137), Heilongjiang Province Postdoctoral Research Start up Fund, The First Affiliated Hospital of Harbin Medical University Research Fund. Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. The KEGG pathway maps used in this study were obtained from the KEGG database (Kanehisa Laboratories). Permission for use has been obtained and is available upon request. Competing interests The authors declare no conflict of interest. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Bingxin Huang, Yue Tang and Xinpeng Jiang. Contributor Information Yunpeng Ling, Email: micsling@pku.edu.cn. Mowei Song, Email: smwflower@hotmail.com. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. The KEGG pathway maps used in this study were obtained from the KEGG database (Kanehisa Laboratories). Permission for use has been obtained and is available upon request.